Home > Resources > Whitepapers > Silicones for pharmaceutical applications –analytical capabilities at Solvias

Silicones for pharmaceutical applications –analytical capabilities at Solvias

Silicones are used in pharmaceutical applications as part of formulations, as well as during manufacturing and in packaging. The term ‘silicones’ encompasses a large number of compounds based on polydialkylsiloxanes. The most common are trimethylsilyl-terminated polydimethylsiloxanes. Dimethicones and simethicones are used as active ingredients and antifoaming agents in numerous anti-flatulent or anti-acid formulations. In pharmaceutical formulations, while considered active ingredients, their effect is usually caused by their physical properties, as polydimethylsiloxanes are not metabolized.

Spotlight

Novus Health

Who We Are Novus Health is Canada’s leader in health navigation. For the past 12 years we have been helping our clients and their employees, members and customers navigate the complex and ever-evolving Canadian healthcare system. We are a team of medical, content and technology professionals with offices across Canada, Europe, and the US, with connections to health professionals around the globe.

OTHER WHITEPAPERS

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Asia Pacific as a Clinical Trials Powerhouse

whitePaper | October 6, 2022

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case,

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

whitePaper | July 1, 2023

As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.

More Whitepapers

Silicones for pharmaceutical applications –analytical capabilities at Solvias